ResMed Inc. (RMD)
After hours:
| Previous close | 164.00 |
| Open | 163.84 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 162.05 - 164.74 |
| 52-week range | 132.24 - 243.52 |
| Volume | |
| Avg. volume | 1,509,484 |
| Market cap | 24.048B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 26.58 |
| EPS (TTM) | 6.15 |
| Earnings date | 24 Jan 2024 - 29 Jan 2024 |
| Forward dividend & yield | 1.92 (1.17%) |
| Ex-dividend date | 08 Nov 2023 |
| 1y target est | 178.38 |
GlobeNewswireStudy Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
Published in the Journal of the American Medical Association Network Open, study estimates global COPD burden from 2020 through 2050 Study projects disproportionate growth in COPD among women and low-middle income regions SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the results of a study on the global burden of Chronic Obstructive Pulmonary Disease (COPD) through 2050. Published in the Journal of the American Medical Association (JAMA) Network Open,
ZacksWhy ResMed (RMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ZacksEnvista (NVST) Up 6.8% Since Last Earnings Report: Can It Continue?
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
